Journal of Bioequivalence & Bioavailability

Fact file of Levofloxacin and risk factors of OH affiliated matrix impurity, disregards impurity and specified impurity associated undetectable impurity: An extended study of second generation antibiotics

10^th World Congress on Bioavailability and Bioequivalence

April 08-09, 2019 Abu Dhabi, UAE

Rahul A Hajare

Indian Council of Medical Research, India

Scientific Tracks Abstracts: J Bioequiv Availab

Abstract:

To highlight this important part of the research process, we asked research scientists to speak about their own experiences with failure. Research scientist explains why considers non-significant and negative studies to be important parts of publication history. Licensed data by USFDA Levofloxacin, but pregnancy category risk not ruled out. Levofloxacin identified by IUPAC (3S)-9-Fluor-3-methyl-10-(4-methyl-1-piperazinyl)- 7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]chinolin-6-carbons�ure, by the end of 6-carboxylic acid group. Legal status is general prescription only. Levofloxacin was approved for medical use in the United States in 1996. It is on the world health organization's list of essential medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world is about 0.44 to 0.95 USD per week of treatment. In the United States a week of treatment costs about 50 to 100 USD. As of 2016, the US Food and Drug Administration (FDA) recommended that "serious side effects associated with OH side antibacterial drugs generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, OH should be inherent impurity seen in Levofloxacin. Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic. It is used to treat a number of bacterial infection including acute bacterial, sinusitis, Pneumonia and urinary infection, chronic prostatitis.

Biography :

Rahul A Hajare is Fellow of Indian Council of Medical Research, New Delhi, India. He is PhD student of reputed University Vinayaka Mission Research Foundation, Salem, Tamil Nadu. He is a winner of World Academic Championship-2017 in Pharmacy (Antiretroviral Therapy). He is among world's 500 most influential experts in pharmacy for the year 2017 on earth. He is also an alumni of The Yoga Institute Centenary Celebration Mumbai.

E-mail: rahulhajare17@gmail.com